Deepesh Patel, MD
Internal Medicine · Poughkeepsie, NYNPI 1720022486
Payments from drug & device makers
Across 155 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$981
- Sunovion Pharmaceuticals Inc.$694
- Johnson & Johnson$679
- Boehringer Ingelheim$315
- Neurocrine Biosciences, Inc.$278
- Lilly USA, LLC$250
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,31097%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $981 |
| Sunovion Pharmaceuticals Inc. | 31 | $694 |
| Johnson & Johnson(2 entities) | 22 | $679 |
| Boehringer Ingelheim | 3 | $315 |
| Neurocrine Biosciences, Inc. | 8 | $278 |
| Lilly USA, LLC | 11 | $250 |
| GSK | 11 | $183 |
| AstraZeneca | 3 | $153 |
| Avanir Pharmaceuticals, Inc. | 2 | $147 |
| Mylan Specialty L.p. | 2 | $141 |
| AbbVie(2 entities) | 3 | $137 |
| Amgen | 2 | $106 |
| Scilex Pharmaceuticals Inc. | 5 | $83 |
| Novartis | 4 | $63 |
| Novo Nordisk | 3 | $53 |
| Pfizer | 3 | $48 |
| Merck | 2 | $33 |
| Insulet Corporation | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,430 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,641 | $490,508 |
| RexultiBrexpiprazole | 275 | $229,402 |
| Tetrabenazine | 41 | $197,622 |
| NuplazidPimavanserin Tartrate | 45 | $128,919 |
| TrulicityDulaglutide | 168 | $128,231 |
| IngrezzaValbenazine Tosylate | 21 | $121,517 |
| XareltoRivaroxaban | 307 | $97,385 |
| OzempicSemaglutide | 64 | $65,960 |
| Abilify MaintenaAripiprazole | 23 | $60,493 |
| JanuviaSitagliptin Phosphate | 185 | $59,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $51,145 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,959 |
| Incruse ElliptaUmeclidinium Bromide | 157 | $50,494 |
| EntrestoSacubitril/Valsartan | 130 | $50,471 |
| UzedyRisperidone | 15 | $49,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $490,5081,641 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy | $183 | $160,894413 claims |
| Acadia Pharmaceuticals IncNuplazid | $15 | $128,91945 claims |
| Lilly USA, LLCTrulicity | $250 | $128,231168 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $278 | $121,51721 claims |
| Johnson & JohnsonXarelto, Procrit | $679 | $113,254329 claims |
| AbbVieCreon, Vraylar, Linzess | $137 | $95,972138 claims |
| MerckJanuvia, Lagevrio (Eua) | $33 | $75,243201 claims |
| Novo NordiskOzempic | $53 | $65,96064 claims |
| NovartisEntresto | $63 | $50,471130 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $981 | $49,62315 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $315 | $47,172108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Poughkeepsie
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.